Business
Avacta Establishes Scientific Advisory Board
Avacta Establishes Scientific Advisory Board.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 1837R Avacta Group PLC 07 March 2016 \n\n7 March 2016\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nAvacta Life Sciences Establishes Scientific Advisory Board\n \nAvacta appoints three world class scientists to guide the strategy for Affimer therapeutic development \n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it has appointed three leading immunologists, Professors Terence Rabbitts, Paul Moss and Adrian Hayday, to form its Scientific Advisory Board which is to be chaired by Non-Executive Director Dr Mike Owen. \n \nDr Owen was Senior Vice President and Global Head of Research of the Biopharmaceuticals R&D Unit at GlaxoSmithKline where he was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline during the last decade through in-house development and through acquisitions such as Domantis. He was appointed as Non-Executive Director of Avacta in September 2015 to bring extensive clinical trial, scientific and commercial experience of therapeutic development and to establish and chair a Scientific Advisory Board to support the development of Affimers as a therapeutic platform technology. \n \nThe Company has today appointed three pre-eminent biologists to form the Scientific Advisory Board: Professor Terrence Rabbitts of the University of Oxford and John Radcliffe Hospital, Professor Adrian Hayday of the Crick Institute King's College and Guy's Hospital, and Professor Paul Moss, Director of the School of Cancer Sciences at Birmingham University and Honorary Consultant at the University Hospitals Birmingham NHS Foundation Trust.\n \nCollectively, this group of internationally recognised scientists has made numerous pivotal discoveries in immunology, ranging from fundamental studies on the genes and proteins that regulate the adaptive immune system to the development of treatments for cancers, and has published several hundred scientific papers on these subjects. They sit on a number of Scientific Advisory Boards for pharmaceutical and biotechnology companies, public and private funding bodies and charities. They bring a very high level of scientific knowledge and experience in translational science an...